zoledronic acid has been researched along with Giant Cell Arteritis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abou Zahr, Z; Ji, Y; Mahmood, SB; Peng, Y | 1 |
| Arkfeld, DG; Ibrahim, M; Metyas, S; Solyman, J; Yeter, KC | 1 |
2 other study(ies) available for zoledronic acid and Giant Cell Arteritis
| Article | Year |
|---|---|
Incidence of giant cell arteritis after bisphosphonate exposure: A retrospective cohort study.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Databases, Factual; Female; Giant Cell Arteritis; Humans; Ibandronic Acid; Incidence; Male; Medicare; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; United States; Zoledronic Acid | 2021 |
Giant cell arteritis with visual loss following zoledronic acid infusion.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Giant Cell Arteritis; Glucocorticoids; Humans; Imidazoles; Infusions, Parenteral; Osteoporosis; Treatment Outcome; Vision Disorders; Vision, Ocular; Zoledronic Acid | 2014 |